Immunotherapy in Myeloproliferative Diseases

被引:18
作者
Braun, Lukas M. [1 ,2 ]
Zeiser, Robert [1 ,3 ,4 ,5 ,6 ]
机构
[1] Univ Freiburg, Med Ctr, Fac Med, Dept Med 1, D-79106 Freiburg, Germany
[2] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany
[3] German Canc Res Ctr, Partner Site Freiburg, German Canc Consortium DKTK, D-69120 Heidelberg, Germany
[4] Univ Freiburg, Comprehens Canc Ctr Freiburg CCCF, D-79106 Freiburg, Germany
[5] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, D-79104 Freiburg, Germany
[6] Univ Freiburg, Ctr Integrat Biol Signalling Studies CIBSS, D-79104 Freiburg, Germany
基金
欧洲研究理事会;
关键词
allo-HSCT; AML; CD123; IFN alpha; immune checkpoint; immunotherapy; inflammation; immune escape; JAK2; MDS; MDSCs; MPN; myeloproliferation; tumor vaccination; STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; TOXIN-INTERLEUKIN-3 FUSION PROTEIN; ACUTE MYELOGENOUS LEUKEMIA; CANCER TESTIS ANTIGEN; RECEPTOR-ALPHA CHAIN; TYROSINE KINASE JAK2; T-REGULATORY CELLS; GROWTH-FACTOR-BETA; FUNCTION IN-VITRO;
D O I
10.3390/cells9061559
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Myeloproliferative diseases, including myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS), are driven by genetic abnormalities and increased inflammatory signaling and are at high risk to transform into acute myeloid leukemia (AML). Myeloid-derived suppressor cells were reported to enhance leukemia immune escape by suppressing an effective anti-tumor immune response. MPNs are a potentially immunogenic disease as shown by their response to interferon-alpha treatment and allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Novel immunotherapeutic approaches such as immune checkpoint inhibition, tumor vaccination, or cellular therapies using target-specific lymphocytes have so far not shown strong therapeutic efficacy. Potential reasons could be the pro-inflammatory and immunosuppressive microenvironment in the bone marrow of patients with MPN, driving tumor immune escape. In this review, we discuss the biology of MPNs with respect to the pro-inflammatory milieu in the bone marrow (BM) and potential immunotherapeutic approaches.
引用
收藏
页数:30
相关论文
共 209 条
[1]   Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias [J].
Abdel-Wahab, Omar ;
Manshouri, Taghi ;
Patel, Jay ;
Harris, Kelly ;
Yao, JinJuan ;
Hedvat, Cyrus ;
Heguy, Adriana ;
Bueso-Ramos, Carlos ;
Kantarjian, Hagop ;
Levine, Ross L. ;
Verstovsek, Srdan .
CANCER RESEARCH, 2010, 70 (02) :447-452
[2]   First Preclinical Report of the Efficacy and PD Results of KHK2823, a Non-Fucosylated Fully Human Monoclonal Antibody Against IL-3Rα [J].
Akiyama, Tadakazu ;
Takayanagi, Shin-ichiro ;
Maekawa, Yoshimi ;
Miyawaki, Kohta ;
Jinnouchi, Fumiaki ;
Jiromaru, Takashi ;
Sugio, Takeshi ;
Daitoku, Shinya ;
Kusumoto, Hirotake ;
Shimabe, Munetake ;
Nishikawa, Satoshi ;
Yamawaki, Kengo ;
Iijima, Kousuke ;
Hiura, Masanori ;
Takahashi, Takeshi ;
Kikushige, Yoshikane ;
Iwasaki, Hiromi ;
Akashi, Koichi ;
Tawara, Tomonori .
BLOOD, 2015, 126 (23)
[3]   Risk models predicting survival after reduced-intensity transplantation for myelofibrosis [J].
Alchalby, Haefaa ;
Yunus, Dinah-Rohina ;
Zabelina, Tatjana ;
Kobbe, Guido ;
Holler, Ernst ;
Bornhaeuser, Martin ;
Schwerdtfeger, Rainer ;
Bethge, Wolfgang ;
Kvasnicka, Hans Michael ;
Buesche, Guntram ;
Ayuk, Francis ;
Bacher, Ulrike ;
Zander, Axel. R. ;
Kroeger, Nicolaus .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (01) :75-85
[4]   Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies [J].
Alkharabsheh, Omar ;
Frankel, Arthur E. .
BIOMEDICINES, 2019, 7 (01)
[5]  
Allegra A, 2009, TUMORI J, V95, P404
[6]   The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells [J].
Almstedt, Maika ;
Blagitko-Dorfs, Nadja ;
Duque-Afonso, Jesus ;
Karbach, Julia ;
Pfeifer, Dietmar ;
Jaeger, Elke ;
Luebbert, Michael .
LEUKEMIA RESEARCH, 2010, 34 (07) :899-905
[7]   Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis [J].
Anderson, JE ;
Sale, G ;
Appelbaum, FR ;
Chauncey, TR ;
Storb, R .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (04) :1010-1016
[8]  
[Anonymous], BLOOD BLOOD, DOI DOI 10.1182/BLOOD.V126.23.1370.1370
[9]  
[Anonymous], 2014, BLOOD, DOI DOI 10.1182/BLOOD.V124.21.120.120
[10]  
[Anonymous], 2019, BLOOD S1, DOI DOI 10.1182/blood-2019-131217